Therapeutic Options for NTRK-Mutated Thyroid Cancer

Targeting NTRK Fusions in Advanced NSCLC Leads Deep Responses

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, MBA, FACP, FCCP, discussed the role of larotrectinib in a patient with NTRK fusion–positive cancer.

Response to Larotrectinib in NTRK+ Thyroid Cancer Differs By Subtype

Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.

Larotrectinib Shows High Efficacy in Differentiated Thyroid Cancer

Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.